Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 11/2013

01-11-2013 | Review Article

MicroRNAs mark in the MLL-rearranged leukemia

Authors: Leonidas Benetatos, George Vartholomatos

Published in: Annals of Hematology | Issue 11/2013

Login to get access

Abstract

MicroRNAs are short noncoding RNAs, known regulators of several signaling pathways cell differentiation and proliferation, development, and apoptosis, which are deregulated in acute leukemia. Mixed lineage leukemia (MLL) gene encodes a protein with histone methyltransferase activity, which is essential for the fine tuning of hematopoietic stem cell development and differentiation through the regulation of HOXA and MEIS1. MLL gene rearrangements characterize both acute myeloid and acute lymphoblastic leukemia associated with poor outcomes. MicroRNAs and MLL rearrangements are in tight association regulating each other expression, affecting cell cycle regulators, and composing complex networks with factors involved in leukemogenesis such as MYC and FLT3. MLL fusion genes are also capable of recruiting DNA methyltransferases at microRNAs promoters controlling their expression through epigenetic changes. Direct drug targeting of MLL has been difficult to achieve, and in this context, microRNA expression modulation represents an attractive approach.
Literature
1.
Zhou H, Hu H, Lai M (2010) Non-coding RNAs and their epigenetic regulatory mechanisms. Biol Cell 102:645–655PubMedCrossRef
2.
Röther S, Meister G (2011) Small RNAs derived from longer non-coding RNAs. Biochimie 93:1905–1915PubMedCrossRef
3.
Sana J, Faltejskova P, Svoboda M, Slaby O (2012) Novel classes of non-coding RNAs and cancer. J Transl Med 10:103PubMedCrossRef
4.
Kim VN, Han J, Siomi MC (2009) Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 10:126–139PubMedCrossRef
5.
Yang JS, Lai EC (2011) Alternative miRNA biogenesis pathways and the interpretation of core miRNA pathway mutants. Mol Cell 43:892–903PubMedCrossRef
6.
Maurin T, Cazalla D, Yang JS, Bortolamiol-Becet D, Lai EC (2012) RNase III-independent microRNA biogenesis in mammalian cells. RNA 18:2166–2173PubMedCrossRef
7.
Zisoulis DG, Kai ZS, Chang RK, Pasquinelli AE (2012) Autoregulation of microRNA biogenesis by let-7 and Argonaute. Nature 486:541–544PubMed
8.
Xhemalce B, Robson SC, Kouzarides T (2012) Human RNA methyltransferase BCDIN3D regulates microRNA processing. Cell 151:278–288PubMedCrossRef
9.
10.
11.
Benetatos L, Voulgaris E, Vartholomatos G, Hatzimichael E (2012) Non-coding RNAs and EZH2 interactions in cancer: long and short tales from the transcriptome. Int J Cancer. doi:10.​1002/​ijc.​27859 PubMed
12.
Iorio MV, Piovan C, Croce CM (2010) Interplay between microRNAs and the epigenetic machinery: an intricate network. Biochim Biophys Acta 1799:694–701PubMedCrossRef
13.
Djuranovic S, Nahvi A, Green R (2012) miRNA-mediated gene silencing by translational repression followed by mRNA deadenylation and decay. Science 336:237–240PubMedCrossRef
14.
Bazzini AA, Lee MT, Giraldez AJ (2012) Ribosome profiling shows that miR-430 reduces translation before causing mRNA decay in zebrafish. Science 336:233–237PubMedCrossRef
15.
Fukaya T, Tomari Y. (2012) MicroRNAs mediate gene silencing via multiple different pathways in Drosophila. Mol Cell 48:825–836
16.
Fukunaga R, Han BW, Hung JH, Xu J, Weng Z, Zamore PD (2012) Dicer partner proteins tune the length of mature miRNAs in flies and mammals. Cell 151:533–546PubMedCrossRef
17.
Rüegger S, Großhans H (2012) MicroRNA turnover: when, how, and why. Trends Biochem Sci 37:436–346PubMedCrossRef
18.
Inui M, Martello G, Piccolo S (2010) MicroRNA control of signal transduction. Nat Rev Mol Cell Biol 11:252–263PubMedCrossRef
19.
Leonardo TR, Schultheisz HL, Loring JF, Laurent LC (2012) The functions of microRNAs in pluripotency and reprogramming. Nat Cell Biol 14:1114–1121PubMedCrossRef
20.
Li MA, He L (2012) microRNAs as novel regulators of stem cell pluripotency and somatic cell reprogramming. BioEssays 34:670–680PubMedCrossRef
21.
Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M (2012) microRNAs in cancer management. Lancet Oncol 13:e249–e258PubMedCrossRef
22.
Nair VS, Maeda LS, Ioannidis JP (2012) Clinical outcome prediction by microRNAs in human cancer: a systematic review. J Natl Cancer Inst 104:528–540PubMedCrossRef
23.
24.
Sotiropoulou G, Pampalakis G, Lianidou E, Mourelatos Z (2009) Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell. RNA 15:1443–1461PubMedCrossRef
25.
Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, Dupont S, Enzo E, Guzzardo V, Rondina M, Spruce T, Parenti AR, Daidone MG, Bicciato S, Piccolo S (2010) A microRNA targeting dicer for metastasis control. Cell 141:1195–1207PubMedCrossRef
26.
Zhao H, Wang D, Du W, Gu D, Yang R (2010) MicroRNA and leukemia: tiny molecule, great function. Crit Rev Oncol Hematol 74:149–155PubMedCrossRef
27.
Navarro F, Lieberman J (2010) Small RNAs guide hematopoietic cell differentiation and function. J Immunol 184:5939–5947PubMedCrossRef
28.
Pfaff N, Moritz T, Thum T, Cantz T (2012) miRNAs involved in the generation, maintenance, and differentiation of pluripotent cells. J Mol Med (Berl) 90:747–752CrossRef
29.
El Gazzar M, McCall CE (2012) MicroRNAs regulatory networks in myeloid lineage development and differentiation: regulators of the regulators. Immunol Cell Biol 90:587–593PubMedCrossRef
30.
31.
Zhang L, Sankaran VG, Lodish HF (2012) MicroRNAs in erythroid and megakaryocytic differentiation and megakaryocyte-erythroid progenitor lineage commitment. Leukemia 26:2310–2316PubMedCrossRef
32.
Schotte D, Pieters R, Den Boer ML (2012) MicroRNAs in acute leukemia: from biological players to clinical contributors. Leukemia 26:1–12PubMedCrossRef
33.
Marcucci G, Mrózek K, Radmacher MD, Garzon R, Bloomfield CD (2011) The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood 117:1121–1129PubMedCrossRef
34.
Benetatos L, Vartholomatos G (2012) Deregulated microRNAs in multiple myeloma. Cancer 118:878–887PubMedCrossRef
35.
Ward BP, Tsongalis GJ, Kaur P (2011) MicroRNAs in chronic lymphocytic leukemia. Exp Mol Pathol 90:173–178PubMedCrossRef
36.
37.
Cosgrove MS, Patel A (2010) Mixed lineage leukemia: a structure-function perspective of the MLL1 protein. FEBS J 277:1832–1842PubMedCrossRef
38.
Ansari KI, Mandal SS (2010) Mixed lineage leukemia: roles in gene expression, hormone signaling and mRNA processing. FEBS J 277:1790–1804PubMedCrossRef
39.
Uribesalgo I, Di Croce L (2011) Dynamics of epigenetic modifications in leukemia. Brief Funct Genomics 10:18–29PubMedCrossRef
40.
Bertani S, Sauer S, Bolotin E, Sauer F (2011) The noncoding RNA Mistral activates Hoxa6 and Hoxa7 expression and stem cell differentiation by recruiting MLL1 to chromatin. Mol Cell 43:1040–1046PubMedCrossRef
41.
Wang KC, Yang YW, Liu B, Sanyal A, Corces-Zimmerman R, Chen Y, Lajoie BR, Protacio A, Flynn RA, Gupta RA, Wysocka J, Lei M, Dekker J, Helms JA, Chang HY (2011) A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression. Nature 472:120–124PubMedCrossRef
42.
Somervaille TC, Matheny CJ, Spencer GJ, Iwasaki M, Rinn JL, Witten DM, Chang HY, Shurtleff SA, Downing JR, Cleary ML (2009) Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell 4:129–140PubMedCrossRef
43.
44.
45.
Cerveira N, Bizarro S, Teixeira MR (2011) MLL-SEPTIN gene fusions in hematological malignancies. Biol Chem 392:713–724PubMedCrossRef
46.
Marcucci G, Haferlach T, Döhner H (2011) Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 29:475–486PubMedCrossRef
47.
Grossmann V, Schnittger S, Kohlmann A, Eder C, Roller A, Dicker F, Schmid C, Wendtner CM, Staib P, Serve H, Kreuzer KA, Kern W, Haferlach T, Haferlach C (2012) A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood 120:2963–2972PubMedCrossRef
48.
Cerveira N, Lisboa S, Correia C, Bizarro S, Santos J, Torres L, Vieira J, Barros-Silva JD, Pereira D, Moreira C, Meyer C, Oliva T, Moreira I, Martins Â, Viterbo L, Costa V, Marschalek R, Pinto A, Mariz JM, Teixeira MR (2012) Genetic and clinical characterization of 45 acute leukemia patients with MLL gene rearrangements from a single institution. Mol Oncol 6:553–564PubMedCrossRef
49.
Guenther MG, Jenner RG, Chevalier B, Nakamura T, Croce CM, Canaani E, Young RA (2005) Global and Hox-specific roles for the MLL1 methyltransferase. Proc Natl Acad Sci U S A 102:8603–8608PubMedCrossRef
50.
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR (2005) MicroRNA expression profiles classify human cancers. Nature 435:834–838PubMedCrossRef
51.
de Oliveira JC, Brassesco MS, Scrideli CA, Tone LG, Narendran A (2012) MicroRNA expression and activity in pediatric acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer 59:599–604PubMedCrossRef
52.
Arnold CP, Tan R, Zhou B, Yue SB, Schaffert S, Biggs JR, Doyonnas R, Lo MC, Perry JM, Renault VM, Sacco A, Somervaille T, Viatour P, Brunet A, Cleary ML, Li L, Sage J, Zhang DE, Blau HM, Chen C, Chen CZ (2011) MicroRNA programs in normal and aberrant stem and progenitor cells. Genome Res 21:798–810PubMedCrossRef
53.
Nakamura T, Canaani E, Croce CM (2007) Oncogenic All1 fusion proteins target Drosha-mediated microRNA processing. Proc Natl Acad Sci U S A 104:10980–10985PubMedCrossRef
54.
Harnprasopwat R, Ha D, Toyoshima T, Lodish H, Tojo A, Kotani A (2010) Alteration of processing induced by a single nucleotide polymorphism in pri-miR-126. Biochem Biophys Res Commun 399:117–122PubMedCrossRef
55.
Kotani A, Ha D, Schotte D, den Boer ML, Armstrong SA, Lodish HF (2010) A novel mutation in the miR-128b gene reduces miRNA processing and leads to glucocorticoid resistance of MLL-AF4 acute lymphocytic leukemia cells. Cell Cycle 9:1037–1042PubMedCrossRef
56.
Kotani A, Ha D, Hsieh J, Rao PK, Schotte D, den Boer ML, Armstrong SA, Lodish HF (2009) miR-128b is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221. Blood 114:4169–4178PubMedCrossRef
57.
Dou L, Zheng D, Li J, Li Y, Gao L, Wang L, Yu L (2012) Methylation-mediated repression of microRNA-143 enhances MLL-AF4oncogene expression. Oncogene 31:507–517PubMedCrossRef
58.
Stumpel DJ, Schotte D, Lange-Turenhout EA, Schneider P, Seslija L, de Menezes RX, Marquez VE, Pieters R, den Boer ML, Stam RW (2011) Hypermethylation of specific microRNA genes in MLL-rearranged infant acute lymphoblastic leukemia: major matters at a micro scale. Leukemia 25:429–439PubMedCrossRef
59.
Nishi M, Eguchi-Ishimae M, Wu Z, Gao W, Iwabuki H, Kawakami S, Tauchi H, Inukai T, Sugita K, Hamasaki Y, Ishii E, Eguchi M (2012) Suppression of the let-7b microRNA pathway by DNA hypermethylation in infant acute lymphoblastic leukemia with MLL gene rearrangements. Leukemia. doi:10.​1038/​leu.​2012.​242 PubMed
60.
Schotte D, Chau JC, Sylvester G, Liu G, Chen C, van der Velden VH, Broekhuis MJ, Peters TC, Pieters R, den Boer ML (2009) Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia. Leukemia 23:313–322PubMedCrossRef
61.
Schotte D, Lange-Turenhout EA, Stumpel DJ, Stam RW, Buijs-Gladdines JG, Meijerink JP, Pieters R, Den Boer ML (2010) Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia. Haematologica 95:1675–1682PubMedCrossRef
62.
Schotte D, De Menezes RX, Akbari Moqadam F, Khankahdani LM, Lange-Turenhout E, Chen C, Pieters R, Den Boer ML (2011) MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia. Haematologica 96:703–711PubMedCrossRef
63.
Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, Levine JE, Wang J, Hahn WC, Gilliland DG, Golub TR, Armstrong SA (2006) Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442:818–822PubMedCrossRef
64.
Chen W, Kumar AR, Hudson WA, Li Q, Wu B, Staggs RA, Lund EA, Sam TN, Kersey JH (2008) Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells. Cancer Cell 13:432–440PubMedCrossRef
65.
Mi S, Lu J, Sun M, Li Z, Zhang H, Neilly MB, Wang Y, Qian Z, Jin J, Zhang Y, Bohlander SK, Le Beau MM, Larson RA, Golub TR, Rowley JD, Chen J (2007) MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci U S A 104:19971–19976PubMedCrossRef
66.
Chandra P, Luthra R, Zuo Z, Yao H, Ravandi F, Reddy N, Garcia-Manero G, Kantarjian H, Jones D (2010) Acute myeloid leukemia with t(9;11)(p21-22;q23): common properties of dysregulated ras pathway signaling and genomic progression characterize de novo and therapy-related cases. Am J Clin Pathol 133:686–693PubMedCrossRef
67.
Li Z, Lu J, Sun M, Mi S, Zhang H, Luo RT, Chen P, Wang Y, Yan M, Qian Z, Neilly MB, Jin J, Zhang Y, Bohlander SK, Zhang DE, Larson RA, Le Beau MM, Thirman MJ, Golub TR, Rowley JD, Chen J (2008) Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A 105:15535–15540PubMedCrossRef
68.
Mi S, Li Z, Chen P, He C, Cao D, Elkahloun A, Lu J, Pelloso LA, Wunderlich M, Huang H, Luo RT, Sun M, He M, Neilly MB, Zeleznik-Le NJ, Thirman MJ, Mulloy JC, Liu PP, Rowley JD, Chen J (2010) Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia. Proc Natl Acad Sci U S A 107:3710–3715PubMedCrossRef
69.
Li Z, Luo RT, Mi S, Sun M, Chen P, Bao J, Neilly MB, Jayathilaka N, Johnson DS, Wang L, Lavau C, Zhang Y, Tseng C, Zhang X, Wang J, Yu J, Yang H, Wang SM, Rowley JD, Chen J, Thirman MJ (2009) Consistent deregulation of gene expression between human and murine MLL rearrangement leukemias. Cancer Res 69:1109–1116PubMedCrossRef
70.
Jiang X, Huang H, Li Z, Li Y, Wang X, Gurbuxani S, Chen P, He C, You D, Zhang S, Wang J, Arnovitz S, Elkahloun A, Price C, Hong GM, Ren H, Kunjamma RB, Neilly MB, Matthews JM, Xu M, Larson RA, Le Beau MM, Slany RK, Liu PP, Lu J, Zhang J, He C, Chen J (2012) Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia. Cancer Cell 22:524–535PubMedCrossRef
71.
Danen-van Oorschot AA, Kuipers JE, Arentsen-Peters S, Schotte D, de Haas V, Trka J, Baruchel A, Reinhardt D, Pieters R, Zwaan CM, van den Heuvel-Eibrink MM (2012) Differentially expressed miRNAs in cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Pediatr Blood Cancer 58:715–721PubMedCrossRef
72.
Li Z, Huang H, Chen P, He M, Li Y, Arnovitz S, Jiang X, He C, Hyjek E, Zhang J, Zhang Z, Elkahloun A, Cao D, Shen C, Wunderlich M, Wang Y, Neilly MB, Jin J, Wei M, Lu J, Valk PJ, Delwel R, Lowenberg B, Le Beau MM, Vardiman J, Mulloy JC, Zeleznik-Le NJ, Liu PP, Zhang J, Chen J (2012) miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia. Nat Commun 3:688PubMedCrossRef
73.
Jiang X, Huang H, Li Z, He C, Li Y, Chen P, Gurbuxani S, Arnovitz S, Hong GM, Price C, Ren H, Kunjamma RB, Neilly MB, Salat J, Wunderlich M, Slany RK, Zhang Y, Larson RA, Le Beau MM, Mulloy JC, Rowley JD, Chen J (2012) miR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia. Proc Natl Acad Sci U S A 109:19397–19402PubMedCrossRef
74.
Forrest AR, Kanamori-Katayama M, Tomaru Y, Lassmann T, Ninomiya N, Takahashi Y, de Hoon MJ, Kubosaki A, Kaiho A, Suzuki M, Yasuda J, Kawai J, Hayashizaki Y, Hume DA, Suzuki H (2010) Induction of microRNAs, mir-155, mir-222, mir-424 and mir-503, promotes monocytic differentiation through combinatorial regulation. Leukemia 24:460–466PubMedCrossRef
75.
Wang XS, Gong JN, Yu J, Wang F, Zhang XH, Yin XL, Tan ZQ, Luo ZM, Yang GH, Shen C, Zhang JW (2012) MicroRNA-29a and microRNA-142-3p are regulators of myeloid differentiation and acute myeloid leukemia. Blood 19:4992–5004CrossRef
76.
Xiong Y, Li Z, Ji M, Tan AC, Bemis J, Tse JV, Huang G, Park J, Ji C, Chen J, Bemis LT, Bunting KD, Tse W (2011) MIR29B regulates expression of MLLT11 (AF1Q), an MLL fusion partner, and low MIR29B expression associates with adverse cytogenetics and poor overall survival in AML. Br J Haematol 153:753–757PubMedCrossRef
77.
Shen WF, Hu YL, Uttarwar L, Passegue E, Largman C (2008) MicroRNA-126 regulates HOXA9 by binding to the homeobox. Mol Cell Biol 28:4609–4619PubMedCrossRef
78.
Whitman SP, Caligiuri MA, Maharry K, Radmacher MD, Kohlschmidt J, Becker H, Mrózek K, Wu YZ, Schwind S, Metzeler KH, Mendler JH, Wen J, Baer MR, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Larson RA, Marcucci G, Bloomfield CD (2012) The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia. Leukemia 26:1713–1717PubMedCrossRef
79.
Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F, Fabbri M, Coombes K, Alder H, Nakamura T, Flomenberg N, Marcucci G, Calin GA, Kornblau SM, Kantarjian H, Bloomfield CD, Andreeff M, Croce CM (2008) MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 111:3183–3189PubMedCrossRef
80.
Popovic R, Riesbeck LE, Velu CS, Chaubey A, Zhang J, Achille NJ, Erfurth FE, Eaton K, Lu J, Grimes HL, Chen J, Rowley JD, Zeleznik-Le NJ (2009) Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization. Blood 113:3314–3322PubMedCrossRef
81.
Wong P, Iwasaki M, Somervaille TC, Ficara F, Carico C, Arnold C, Chen CZ, Cleary ML (2010) The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression. Cancer Res 70:3833–3842PubMedCrossRef
82.
Chen J, Odenike O, Rowley JD (2010) Leukaemogenesis: more than mutant genes. Nat Rev Cancer 10:23–36PubMedCrossRef
83.
Bernt KM, Armstrong SA (2011) Targeting epigenetic programs in MLL-rearranged leukemias. Hematology Am Soc Hematol Educ Program 2011:354–360PubMedCrossRef
84.
85.
Shi A, Murai MJ, He S, Lund G, Hartley T, Purohit T, Reddy G, Chruszcz M, Grembecka J, Cierpicki T (2012) Structural insights into inhibition of the bivalent menin–MLL interaction by small molecules in leukemia. Blood 20:4461–4469CrossRef
86.
Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, Robson SC, Chung CW, Hopf C, Savitski MM, Huthmacher C, Gudgin E, Lugo D, Beinke S, Chapman TD, Roberts EJ, Soden PE, Auger KR, Mirguet O, Doehner K, Delwel R, Burnett AK, Jeffrey P, Drewes G, Lee K, Huntly BJ, Kouzarides T (2011) Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478:529–533PubMedCrossRef
87.
Senisterra G, Wu H, Allali-Hassani A, Wasney GA, Barsyte-Lovejoy D, Dombrovski L, Dong A, Nguyen KT, Smil D, Bolshan Y, Hajian T, He H, Seitova A, Chau I, Li F, Poda G, Couture JF, Brown PJ, Al-Awar R, Schapira M, Arrowsmith CH, Vedadi M (2013) Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5. Biochem J 449:151–159PubMedCrossRef
88.
Murray MY, Rushworth SA, MacEwan DJ (2012) Micro RNAs as a new therapeutic target towards leukaemia signalling. Cell Signal 24:363–368PubMedCrossRef
Metadata
Title
MicroRNAs mark in the MLL-rearranged leukemia
Authors
Leonidas Benetatos
George Vartholomatos
Publication date
01-11-2013
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 11/2013
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-013-1803-4

Other articles of this Issue 11/2013

Annals of Hematology 11/2013 Go to the issue

Letter to the Editor

Reversible iatrogenic, MTX-associated EBV-driven lymphoproliferation with histopathological features of a lymphomatoid granulomatosis in a patient with rheumatoid arthritis

Original Article

Children and adolescents with follicular lymphoma have an excellent prognosis with either limited chemotherapy or with a “watch and wait” strategy after complete resection

Letter to the Editor

Concerns regarding data supporting recent Pneumocystis jirovecii prophylaxis guidelines

Original Article

Lymphoma-associated hemophagocytic lymphohistiocytosis: experience in adults from a single institution

Original Article

Isolation and characterization of mouse bone marrow-derived Lin−/VEGF-R2+ progenitor cells

Review Article

Follow-up of patients receiving rituximab for diffuse large B cell lymphoma: an overview of systematic reviews
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits